Elevation Oncology, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Joseph J. Ferra Jr.
- Full Time Employees
- 34
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 888 Seventh Avenue Boston NY United States of America 10106
- IPO Date
- Jun 25, 2021
- CIK
- 0001783032
- Website
- elevationoncology.com
- Similar Companies
- Business
- Elevation Oncology, Inc. operates as a clinical-stage biopharmaceutical company specializing in the development of precision oncology therapies targeting genomically defined cancers. The company’s core products include antibody-drug conjugates (ADCs) focused on selective cancer treatment by inhibiting specific genomic alterations driving tumor growth. Elevation Oncology’s key pipeline candidates include EO-3021, an ADC targeting Claudin 18.2 for advanced gastric and gastroesophageal junction (GEJ) cancers, and EO-1022, a novel HER3-targeted ADC designed to treat HER3-expressing solid tumors such as breast and non-small cell lung cancers. The company deploys glycan site-specific conjugation technologies, leveraging partnerships such as the licensing agreement with Synaffix BV for access to advanced ADC linker-payload technology that enhances therapeutic safety and efficacy. Founded in 2015 and headquartered in New York, Elevation Oncology operates primarily in the United States and focuses on cancers with significant unmet medical needs, aiming to provide purpose-built precision medicines for genetically defined patient populations. The company collaborates strategically with Caris Life Sciences to identify relevant oncogenic mutations and fusions to guide targeted therapy development. Recent major changes include Elevation Oncology’s announcement of a definitive acquisition agreement by Concentra Biosciences in mid-2025, culminating in a merger and subsequent delisting from Nasdaq. In 2024 and 2025, the company reprioritized its development pipeline by halting further investment in programs such as seribantumab and discontinuing development of EO-3021 in early 2025, accompanied by a significant workforce reduction of approximately 70% to realign resources. Additionally, Elevation advanced EO-1022 toward clinical development with plans to file an Investigational New Drug application in 2026 following preclinical proof-of-concept data presentations. The firm continues to focus on novel targeted therapeutics with ongoing trials combining EO-3021 with other immunotherapies before its discontinuation. Elevation Oncology’s strategic positioning centers on precision oncology solutions for solid tumors, utilizing cutting-edge ADC technology platforms and genomic-driven patient selection to optimize clinical outcomes for difficult-to-treat cancers.
HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Elevation Oncology, Inc. (NASDAQ: ELEV)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNW, ELEV, CRKN on Behalf of Shareholders
ELEVATION ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Elevation Oncology, Inc. - ELEV
ELEV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Elevation Oncology, Inc. Is Fair to Shareholders
Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right
Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
Elevation Oncology Plunges 42% on Ending Development of Lead Drug
Elevation Oncology Stops Gastric Cancer Study, Slashes Staff By 70%
Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options
Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements
Elevation Oncology to Participate in Upcoming Investor Conferences
Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones
Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion
Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors
Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024
Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference
Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements
What Makes Elevation Oncology (ELEV) a New Strong Buy Stock